Academic freedom in clinical research

New England Journal of Medicine

Volumn 347, Issue 17, 2002, Pages 1368-1371

  Nathan, David G ^a   Weatherall, David J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATE;

ACADEMIC ACHIEVEMENT; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENTIALITY; DECISION MAKING; DRUG INDUCED DISEASE; ETHICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; IRON OVERLOAD; LIVER FIBROSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; THALASSEMIA; UNITED STATES; UNIVERSITY;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HOSPITAL FOR SICK CHILDREN (TORONTO); UNIVERSITY OF TORONTO;

CANADA; CONFIDENTIALITY; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; FREEDOM; HISTORY, 20TH CENTURY; HOSPITALS, PEDIATRIC; HUMANS; INTERINSTITUTIONAL RELATIONS; IRON CHELATING AGENTS; IRON OVERLOAD; ONTARIO; PUBLISHING; PYRIDONES; RESEARCH SUPPORT; TREATMENT FAILURE; UNIVERSITIES;

EID: 0037168020     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb020394     Document Type: Review

References (30)

1. Is the university-industrial complex out of control? Nature 2001;409:119.
2. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001;345:825-7.
3. Thompson J, Baird P, Downie J. Report of the Committee of Inquiry on the Case Involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex Inc. Toronto: Canadian Association of University Teachers, 2001.
4. Pippard MJ, Weatherall DJ. Oral iron chelation therapy for thalassaemia: An uncertain scene. Br J Haematol 2000;111:2-5.
5. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
6. Hider RC, Singh S, Porter JB, Huehns ER. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann N Y Acad Sci 1990;612:327-38.
7. Berdoukas V, Bentley P, Frost H, Schnebli HP. Toxicity of oral iron chelator Ll. Lancet 1993;341:1088.
8. Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 1992;20:256-61.
9. Choudhury R, Singh S. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat. Drug Metab Dispos 1995;23:314-20.
10. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987;295:1509-12.
11. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
12. Nathan DG. An orally active iron chelator. N Engl J Med 1995;332:953-4. [Erratum, N Engl J Med 1995;332:1315.]
13. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
14. Kowdley KV, Kaplan MM. Iron-chelation therapy with oral deferiprone - toxicity or lack of efficacy? N Engl J Med 1998;339:468-9.
15. Olivieri NF. Long-term followup of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1). Blood 1996;88:Suppl 1:310a. abstract.
16. Letsky EA, Miller F, Worwood M, Flynn DM. Serum ferritin in children with thalassaemia regularly transfused. J Clin Pathol 1974;27:652-5.
17. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-3.
18. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
19. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
20. Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101:413-5.
21. Del Vecchio GC, Crollo E, Schettini P, Schettini F, Fischer R, De Martia D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematol 2000;104:99-102.
22. Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy, a single center interim report on deferiprone (L1) in thalassemia. Haematologica 1998;83:496-501.
23. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
24. Naimark A, Knoppers BM, Lowry FH. Clinical trial of L1 (deferiprone) at the Hospital for Sick Children in Toronto: a review of facts and circumstances. Toronto: Hospital for Sick Children, 1998.
25. Cranton J. Letter to Dr. Laurence Becker. Toronto: College of Physicians and Surgeons of Ontario, December 19, 2001.
26. Naylor CD. The deferiprone controversy: Time to move on. CMAJ 2002;166:452-3.
27. Kern D, Crausman RS, Durand KT, Nayer A, Kuhn C III. Flock worker's lung: Chronic interstitial lung disease in the nylon flocking industry. Ann Intern Med 1998;129:261-72. [Erratum, Ann Intern Med 1999;130: 246.]
28. Davidoff F. New disease, old story. Ann Intern Med 1998;129:327-8. [Erratum, Ann Intern Med 1999;130:246.]
29. Rennie D. Thyroid storm. JAMA 1997;277:1238-43. [Erratum, JAMA 1997;277:1762.]
30. Somerville MA. A postmodern moral tale: The ethics of research relationships. Nat Rev Drug Discov 2002;1:316-20.